Abstract |
Aclarubicin is a new anthracycline antibiotic that produces substantially less cardiotoxicity in animals that does doxorubicin. Based upon prior Phase I and II trials in leukemia, a Phase II study in acute myeloblastic leukemia was developed to assess the response rate and toxicity in previously treated patients. Forty patients received aclarubicin 100 mg/m2 per day X 3 with repeated course on days 14-16 if marrow hypoplasia was not produced. Complete responses were achieved in 27.5% (11/40) with durations of 1.5, 2, 2, 2, 3, 3+, 4, 5+, 32+, 33+, and 34+ months. Toxic effects of this therapy included severe neutropenia and thrombocytopenia, nausea/ vomiting, mucositis, and diarrhea. No patient developed significant changes in the left ventricular ejection fraction, as measured by radionuclide angiography, or any clinical cardiac symptoms. Alopecia was minimal. Aclarubicin can produce a significant response rate in previously treated patients with acute myeloblastic leukemia and should be considered for study in initial therapy.
|
Authors | D C Case Jr, T J Ervin, M A Boyd, L G Bove, H L Sonneborn, S D Paul |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 10
Issue 6
Pg. 523-6
(Dec 1987)
ISSN: 0277-3732 [Print] United States |
PMID | 3479891
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Naphthacenes
- Aclarubicin
|
Topics |
- Aclarubicin
- Adolescent
- Adult
- Aged
- Antibiotics, Antineoplastic
(therapeutic use)
- Drug Evaluation
- Electrocardiography
- Heart
(drug effects)
- Humans
- Leukemia, Myeloid, Acute
(drug therapy)
- Middle Aged
- Naphthacenes
(adverse effects, therapeutic use)
|